{
    "_id": "38289232|None",
    "id": "38289232",
    "infons": {},
    "passages": [
        {
            "infons": {
                "journal": "Blood;2023Dec25. doi:10.1182/blood.2023021598",
                "year": "2023",
                "type": "title",
                "authors": "Benz EJ, Silberstein LE, Panepinto JA, "
            },
            "offset": 0,
            "text": "Blood Spotlight Review on Gene Therapy for Sickle Cell Disease.",
            "sentences": [],
            "annotations": [
                {
                    "id": "1",
                    "infons": {
                        "identifier": "MESH:D000755",
                        "type": "Disease",
                        "valid": true,
                        "normalized": [
                            "D000755"
                        ],
                        "database": "ncbi_mesh",
                        "normalized_id": "D000755",
                        "biotype": "disease",
                        "name": "Anemia Sickle Cell",
                        "accession": "@DISEASE_Anemia_Sickle_Cell"
                    },
                    "text": "Sickle Cell Disease",
                    "locations": [
                        {
                            "offset": 43,
                            "length": 19
                        }
                    ]
                }
            ],
            "relations": []
        },
        {
            "infons": {
                "type": "abstract"
            },
            "offset": 64,
            "text": "The root cause of sickle cell anemia has been known for seven decades, yet no curative therapies have been available other than allogeneic bone marrow transplantation, applicability is limited. Two potentially curative therapies based on gene therapy and gene editing strategies are about to enter the final stages of the FDA approval process. This review surveys the nature of these therapies and the opportunities and issues raised by the prospect of definitive genetically based therapies being available in clinical practice.",
            "sentences": [],
            "annotations": [
                {
                    "id": "3",
                    "infons": {
                        "identifier": "MESH:D000755",
                        "type": "Disease",
                        "valid": true,
                        "normalized": [
                            "D000755"
                        ],
                        "database": "ncbi_mesh",
                        "normalized_id": "D000755",
                        "biotype": "disease",
                        "name": "Anemia Sickle Cell",
                        "accession": "@DISEASE_Anemia_Sickle_Cell"
                    },
                    "text": "sickle cell anemia",
                    "locations": [
                        {
                            "offset": 82,
                            "length": 18
                        }
                    ]
                }
            ],
            "relations": []
        }
    ],
    "relations": [],
    "pmid": 38289232,
    "pmcid": null,
    "meta": {},
    "date": "2023-12-25T00:00:00Z",
    "journal": "Blood",
    "authors": [
        "Benz EJ Jr",
        "Silberstein LE",
        "Panepinto JA"
    ],
    "relations_display": []
}